Adrenal Insufficiency Management

Diagnostic Testing and Electrolyte Monitoring

• For indeterminate results, an ACTH stimulation test may be needed to evaluate adrenal function in patients with suspected adrenal insufficiency, according to the Journal of Clinical Oncology guidelines, which are supported by the American Society of Clinical Oncology 1
• Evaluate electrolytes (sodium, potassium) for signs of adrenal insufficiency, as recommended by the American Society of Clinical Oncology, to monitor for potential complications 1

Patient Education and Management

• All patients with adrenal insufficiency need education on stress dosing, including doubling their current dose during minor illness, receiving IV hydrocortisone for major illness or surgery, and wearing a medical alert bracelet indicating adrenal insufficiency, as advised by the American Society of Clinical Oncology 1, 2
• Patients should follow specific guidelines based on severity grade for managing immune-related adverse events, as recommended by the American Society of Clinical Oncology 1

Corticosteroid Tapering

• Corticosteroid therapy should be tapered gradually over a period of at least 1 month to prevent withdrawal syndrome, with tapering not being too rapid to avoid recurrence or worsening of the underlying condition, as recommended by various medical societies 3
• A structured tapering schedule is recommended to avoid complications, although the exact protocol may vary depending on the patient's condition and the prescribing physician's guidelines 4, 5, 6

• The following general tapering protocol can be considered:

  Tapering Stage	Prednisone Dose	Duration
  Initial taper	40mg to 30mg daily	5-7 days
  	30mg to 20mg daily	5-7 days
  Intermediate taper	20mg to 15mg daily	5-7 days
  	15mg to 10mg daily	5-7 days
  Final taper	10mg to 7.5mg daily	5-7 days
  	7.5mg to 5mg daily	5-7 days
  	5mg to 2.5mg daily	5-7 days

• The tapering protocol should begin with the current dose of 10 mg prednisone daily and reduce the dose by 1 mg every 4 weeks, with a total tapering period of approximately 40 weeks (10 months), as recommended by the American College of Rheumatology 8
• If the patient experiences significant withdrawal symptoms during the standard taper, a slower taper option can be considered, involving reducing the dose by 0.5 mg every 4 weeks instead of 1 mg 9

Monitoring and Follow-up

• The patient should be scheduled for follow-up visits every 4-8 weeks to monitor for symptoms of adrenal insufficiency, such as fatigue, weakness, nausea, vomiting, hypotension, and hypoglycemia 8
• Morning cortisol testing should be considered when reaching doses below 5 mg daily 8
• Regular clinical assessment is necessary for signs of the underlying disease reactivation, symptoms of adrenal insufficiency, and psychiatric symptoms 3
• Patients should be monitored for signs of the underlying condition worsening and for symptoms of adrenal insufficiency, such as fatigue, weakness, dizziness, nausea, and hypotension, during the tapering process, as advised by the American College of Physicians 7

Special Considerations

• Patients with hypopituitarism may require lifelong physiologic replacement of glucocorticoids, and complete discontinuation may not be possible 1, 2
• Symptoms of glucocorticoid withdrawal can overlap with those of the underlying disorder, and patients should be aware of this possibility 1, 2
• The American Gastroenterological Association recommends that all patients receiving corticosteroids should receive 800-1000 mg/day calcium and 800 IU/day vitamin D to prevent bone loss, and patients should use the lowest effective dose for the shortest duration possible 6
• HPA axis suppression should be anticipated in any patient receiving more than 7.5mg of prednisolone equivalent daily for more than 3 weeks, as stated by the European League Against Rheumatism, published in Annals of the Rheumatic Diseases 10
• Patients with pre-existing conditions, such as cirrhosis, have higher frequencies of complications (25% vs 8%), as noted by the American Association for the Study of Liver Diseases 5
• The risk of adverse effects from not tapering prednisone increases with longer durations of therapy, creating greater HPA axis suppression, and is supported by evidence from the American Association for the Study of Liver Diseases 5
• Patients with inflammatory conditions, such as atopic dermatitis, may experience severe flares when prednisone is discontinued abruptly, as documented by the American Academy of Dermatology 4
• In autoimmune hepatitis, abrupt discontinuation can trigger disease exacerbation, as reported by the American Association for the Study of Liver Diseases 5
• Methylprednisolone has 1.25 times the potency of prednisone, and 125mg methylprednisolone IM is equivalent to approximately 156mg prednisone, according to the American College of Physicians, as reported by Praxis Medical Insights 7
• Conversion to hydrocortisone (15-20 mg in divided doses) can be considered when reaching 5 mg prednisone, with a typical regimen of 10 mg on awakening, 5 mg at noon, and 2.5 mg in early afternoon 9